Lynx1 Capital Management as of Dec. 31, 2024
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 18 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Merus N V (MRUS) | 24.9 | $67M | 1.6M | 42.05 | |
| Stoke Therapeutics (STOK) | 21.5 | $57M | 5.2M | 11.03 | |
| Gh Research Ordinary Shares (GHRS) | 12.8 | $34M | 4.9M | 7.00 | |
| C4 Therapeutics Com Stk (CCCC) | 9.2 | $25M | 6.9M | 3.60 | |
| Allogene Therapeutics (ALLO) | 8.7 | $23M | 11M | 2.13 | |
| Tscan Therapeutics (TCRX) | 6.1 | $16M | 5.4M | 3.04 | |
| Cullinan Oncology (CGEM) | 5.7 | $15M | 1.3M | 12.18 | |
| Keros Therapeutics (KROS) | 3.2 | $8.6M | 544k | 15.83 | |
| Passage Bio | 2.0 | $5.2M | 9.3M | 0.57 | |
| Allakos | 1.6 | $4.4M | 3.6M | 1.21 | |
| Upstream Bio (UPB) | 1.5 | $3.9M | 240k | 16.44 | |
| Precision Biosciences Com New (DTIL) | 1.1 | $2.9M | 766k | 3.81 | |
| Ibio Con New (IBIO) | 0.8 | $2.1M | 862k | 2.45 | |
| Caribou Biosciences (CRBU) | 0.4 | $1.1M | 680k | 1.59 | |
| Vor Biopharma | 0.3 | $707k | 637k | 1.11 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.1 | $292k | 17k | 16.75 | |
| Neuphoria Therapeutics (NEUP) | 0.1 | $157k | 46k | 3.43 | |
| Repare Therapeutics Ord | 0.0 | $104k | 79k | 1.31 |
